Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Ho, G.-T.; Moodie, F.M.; Satsangi, J.
May 2003
Gut;May2003, Vol. 52 Issue 5, p759
Academic Journal
The interface between luminal contents and intestinal epithelium constitutes the largest area of interaction between the host and the environment. There is now strong evidence that the gene product of the multidrug resistant pump (MDR) plays a critical role in host-bacterial interactions in the gastrointestinal tract and maintenance of intestinal homeostasis. This review highlights the efflux mechanism in the intestinal epithelium which is mediated by the multidrug resistant pump, also known as P-glycoprotein 170. Current studies promise to provide further insights into the contribution of the MDR1 gene in the pathogenesis of inflammatory and malignant disorders of the gastrointestinal tract.


Related Articles

  • Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Ando, T; Nishimura, M; Oka, Y // Leukemia (08876924);Nov2000, Vol. 14 Issue 11, p1915 

    Multidrug resistance (MDR) is a major problem in patients with hematological malignancies. Although drug-resistance is known to be induced by the expression of P-glycoprotein (P-gp) encoded by the MDR-1 gene, little is known about the mechanisms regulating this gene. Herein, we studied the DNA...

  • Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Matsui, H; Takeshita, A; Naito, K; Shinjo, K; Shigeno, K; Maekawa, M; Yamakawa, Y; Tanimoto, M; Kobayashi, M; Ohnishi, K; Ohno, R // Leukemia (08876924);May2002, Vol. 16 Issue 5, p813 

    Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90% of which express CD33 antigen. However, our recent...

  • EDITORIAL. O'Driscoll, Lorraine // Current Cancer Drug Targets;May2009, Vol. 9 Issue 3, p250 

    The article discusses various reports published within the issue including one about the classical multiple drug resistance (MDR) drug transporters and another on the relation between the drug efflux pump P-glycoprotein and MDR.

  • Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics. Hamilton, K.O.; Yazdanian, M.A.; Audus, K.L. // Current Drug Metabolism;Feb2002, Vol. 3 Issue 1, p1 

    To date, there are few in vitro models of the human lung that have been used to characterize multidrug resistant (MDR) efflux pump activity. It is expected that the presence of these protein transporter molecules, such as P-glycoprotein (Pgp) and the multidrug resistance protein associated...

  • Reversal of Multidrug Resistance by the P-Glycoprotein Modulator, LY335979, from the Bench to the Clinic. Dantzig, A.H.; Law, K.L.; Cao, J.; Starling, J.J. // Current Medicinal Chemistry;Jan2001, Vol. 8 Issue 1, p39 

    Multidrug resistance may be conferred by P-glycoprotein (Pgp, ABCB1) or the multidrug resistance associated protein (MRP). These membrane proteins are members of the ATP binding cassette transporter superfamily and are responsible for the removal from the cell of several anticancer agents...

  • P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. Speicher, Lisa A.; Barone, Linda R. // JNCI: Journal of the National Cancer Institute;5/4/94, Vol. 86 Issue 9, p688 

    Characterizes the interactions of the multidrug resistant phenotype by estramustine with P-glycoprotein. Photoaffinity labeling of membrane fractions; Competitive inhibition of proteins binding with estramustine; Concentration-dependent enhancement of drug accumulation.

  • In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Mistry, P; Plumb, J; Eccles, S; Watson, S; Dale, I; Ryder, H; Box, G; Charlton, P; Templeton, D; Bevan, P B // British Journal of Cancer;4/1/99, Vol. 79 Issue 11/12, p1672 

    Overexpression of P-glycoprotein (P-gp) is a potential cause of multidrug resistance (MDR) in tumours. We have previously reported that XR9051 (N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phenyl)-3- ((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-piperazinylidene)methylbenzam ide)...

  • Research on drug resisitance unearths many molecules, many mechanisms. Reynolds, Tom // JNCI: Journal of the National Cancer Institute;08/05/98, Vol. 90 Issue 15, p1120 

    Part I. Reports on the discovery of the multidrug resistance (MDR) molecule P-glycoprotein (P-gp) in the 1970s. Testing of MDR reversing agents by clinical researchers; What research on drug resistance focused on; Role played by P-gp in protecting healthy cells and tumor cells from cytotoxic...

  • The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Rothnie, Alice; Theron, Daniel; Soceneantu, Loredana; Martin, Catherine; Traikia, Mounir; Berridge, Georgina; Higgins, Christopher F.; Devaux, Philippe F.; Callaghan, Richard // European Biophysics Journal;2001, Vol. 30 Issue 6, p430 

    In tumour cell lines that display multidrug resistance, expression of P-glycoprotein (P-gp) alters many aspects of biomembrane organization in addition to its well-characterized drug transport activity. We have developed a reconstitution system to directly investigate the effect of purified P-gp...

  • P-glycoprotein and substrates: Possible roles of MDR1 gene in the kidney. Ernest, Sylvain; Bello-Reuss, Elsa // Kidney International Supplement;Apr1998, Issue 65, pS-11 

    Examines the functions of the P-glycoproteins (Pgp) encoded by the multidrug resistance (MDR) genes. Role of MDR1 gene in the kidney; Importance of Pgp in renal tissues; Description of MDR.


Read the Article


Sign out of this library

Other Topics